Loading...
Market
Where will the Oxford ovarian cancer vaccine first be tested in human trials by December 31, 2024?
2
Resolution / Starting Odds
United Kingdom • 25%
European Union • 25%
United States • 25%
Other • 25%
Official announcements from Oxford University or trial registries
Story
Oxford Scientists Pioneer World-First Ovarian Cancer Vaccine
Oct 10, 2024, 02:18 PM
Oxford scientists are pioneering a groundbreaking, world-first ovarian cancer vaccine, potentially offering a future cure. The vaccine aims to train the immune system to recognize and attack early-stage ovarian cancer cells. This development is part of ongoing research to make cancer prevention as easy as a flu shot.
View original story
Similar markets
Yes • 50%
No • 50%
Approval for public use • 25%
Widespread distribution • 25%
Inclusion in national vaccination programs • 25%
None of the above • 25%
Preclinical • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 or beyond • 25%
Europe • 25%
United States • 25%
Asia • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
UK • 14%
USA • 14%
Germany • 14%
France • 14%
Japan • 14%
Australia • 14%
Other • 14%
Pfizer • 25%
AstraZeneca • 25%
Johnson & Johnson • 25%
No partnership • 25%
Yes • 50%
No • 50%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
No results announced • 25%